More talk, no action in Genzyme-Sanofi standoff

Genzyme executives may be feeling nauseous every time they ponder Sanofi-Aventis's $18.5 billion offer for the company, but the pharma giant's CFO views the bid as quite "compelling." "Our price is a very good price, compelling," said Jerome Contamine. The CFO also told Reuters that the use of a contingent value right--laying out milestones based on future performance of experimental products like Campath--was "in principle" an interesting way to bridge differences between two parties. But he declined the chance to discuss how a CVR could be used to nail a deal with Genzyme. That leaves both sides continuing to play High Noon, as each waits to see how this standoff will play out. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.